Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 4
1986 2
1987 2
1988 2
1989 4
1990 4
1991 3
1992 1
1993 2
1994 1
1995 1
1996 2
1997 1
1998 3
1999 2
2000 5
2001 4
2002 3
2003 5
2004 7
2005 8
2006 7
2007 4
2008 11
2009 10
2010 5
2011 3
2012 11
2013 18
2014 13
2015 11
2016 13
2017 15
2018 8
2019 9
2020 15
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

191results
Results by year
Filters applied:.Clear all
Page 1
Definitions and diagnosis of pulmonary hypertension.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M,Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Hoeper MM, et al. Among authors:langleben d. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. J Am Coll Cardiol. 2013. PMID:24355641 Free article. Review.
Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM,Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Ghofrani HA, et al. Among authors:langleben d. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655. N Engl J Med. 2013. PMID:23883378 Free article. Clinical Trial.
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents.
McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM,Langleben D, Li M, Sitbon O, Tapson V, Frost A. McLaughlin VV, et al. Among authors:langleben d. Chest. 2020 Apr;157(4):955-965. doi: 10.1016/j.chest.2019.10.043. Epub 2019 Nov 16. Chest. 2020. PMID:31738929 Free article.
Updated clinical classification of pulmonary hypertension.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ,Langleben D, Nakanishi N, Souza R. Simonneau G, et al. Among authors:langleben d. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-54. doi: 10.1016/j.jacc.2009.04.012. J Am Coll Cardiol. 2009. PMID:19555858 Free article. Review.
Clinical classification of pulmonary hypertension.
Simonneau G, Galiè N, Rubin LJ,Langleben D,西格W, Domenighetti G,吉布斯,Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Simonneau G, et al. Among authors:langleben d. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. doi: 10.1016/j.jacc.2004.02.037. J Am Coll Cardiol. 2004. PMID:15194173 Free article. Review.
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M,Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV; Scleroderma Foundation and Pulmonary Hypertension Association. Khanna D, et al. Among authors:langleben d. Arthritis Rheum. 2013 Dec;65(12):3194-201. doi: 10.1002/art.38172. Arthritis Rheum. 2013. PMID:24022584 Free PMC article.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM, Simonneau G, Corris PA, Ghofrani哈,吉隆坡inger JR,Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL. Hoeper MM, et al. Among authors:langleben d. Eur Respir J. 2017 Sep 9;50(3):1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep. Eur Respir J. 2017. PMID:28889107 Free PMC article.
Riociguat: Clinical research and evolving role in therapy.
Klinger JR, Chakinala MM,Langleben D, Rosenkranz S, Sitbon O. Klinger JR, et al. Among authors:langleben d. Br J Clin Pharmacol. 2020 Nov 26. doi: 10.1111/bcp.14676. Online ahead of print. Br J Clin Pharmacol. 2020. PMID:33242341 Review.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK,Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. Barst RJ, et al. Among authors:langleben d. N Engl J Med. 1996 Feb 1;334(5):296-301. doi: 10.1056/NEJM199602013340504. N Engl J Med. 1996. PMID:8532025 Free article. Clinical Trial.
191results
You have reached the last page of results. A maximum of 10,000 results are available.
Jumpto page